Moreover, the anti-IL-6 receptor (IL-6R) antibody tocilizumab can improve the prognosis of critical COVID-19 patients, as it can bind to IL-6R and block downstream signal transduction (10). The gene discussed is IL6R; the disease is COVID-19.